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Outcomes of Surgical Management of
Familial Intrahepatic Cholestasis 1 and
Bile Salt Export Protein Deficiencies
Laura N. Bull,1,2 Ludmila Pawlikowska,2,3 Sandra Strautnieks,4 Irena Jankowska,5 Piotr Czubkowski,5 Jennifer L. Dodge,6
Karan Emerick,7 Catherine Wanty,8 Sami Wali,9 Samra Blanchard,10 Florence Lacaille,11 Jane A. Byrne,4
Albertien M. van Eerde,12 Kaija-Leena Kolho,13,14 Roderick Houwen,15 Steven Lobritto,16 Vera Hupertz,17
Patricia McClean,18 Giorgina Mieli-Vergani,4 Etienne Sokal,8 Philip Rosenthal,19 Peter F. Whitington,20 Joanna Pawlowska,5
and Richard J. Thompson4
Progressive familial intrahepatic cholestasis (PFIC) with normal circulating gamma-glutamyl transpeptidase levels can
result from mutations in the ATP8B1 gene (encoding familial intrahepatic cholestasis 1 [FIC1] deficiency) or the ABCB11
gene (bile salt export protein [BSEP] deficiency). We investigated the outcomes of partial external biliary diversion, ileal
exclusion, and liver transplantation in these two conditions. We conducted a retrospective multicenter study of 42 patients
with FIC1 deficiency (FIC1 patients) and 60 patients with BSEP deficiency (BSEP patients) who had undergone one or
more surgical procedures (57 diversions, 6 exclusions, and 57 transplants). For surgeries performed prior to transplantation,
BSEP patients were divided into two groups, BSEP-common (bearing common missense mutations D482G or E297G,
with likely residual function) and BSEP-other. We evaluated clinical and biochemical outcomes in these patients. Overall,
diversion improved biochemical parameters, pruritus, and growth, with substantial variation in individual response. BSEP-
common or FIC1 patients survived longer after diversion without developing cirrhosis, being listed for or undergoing liver
transplantation, or dying, compared to BSEP-other patients. Transplantation resolved cholestasis in all groups. However,
FIC1 patients commonly developed hepatic steatosis, diarrhea, and/or pancreatic disease after transplant accompanied by
biochemical abnormalities and often had continued poor growth. In BSEP patients with impaired growth, this generally
improved after transplantation. Conclusion: Diversion can improve clinical and biochemical status in FIC1 and BSEP defi-
ciencies, but outcomes differ depending on genetic etiology. For many patients, particularly BSEP-other, diversion is not a
permanent solution and transplantation is required. Although transplantation resolves cholestasis in patients with FIC1
and BSEP deficiencies, the overall outcome remains unsatisfactory in many FIC1 patients; this is mainly due to extrahe-
patic manifestations. (Hepatology Communications 2018;2:515-528)
Familial intrahepatic cholestasis 1 (FIC1) andbile salt export protein (BSEP) deficiencies arethe two most prevalent identified forms of pro-
gressive familial intrahepatic cholestasis (PFIC) with
normal circulating gamma-glutamyl transpeptidase
(GGT) activity.(1-3) FIC1 deficiency results from muta-
tions in the ATPase phospholipid transporting 8B1
(ATP8B1) gene, and BSEP deficiency results from
mutations in the ATP binding cassette subfamily B
member 11 (ABCB11) gene.(1,2,4-6) The severe forms of
both conditions, termed PFIC, present in early child-
hood with progressive liver disease. We have reported
differences in presentation and progression between the
two conditions.(3) PFIC often resists medical therapy
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSEP, bile salt export protein; CI, confidence interval; FIC1,
familial intrahepatic cholestasis 1; FLLN, fold of the lower limit of the normal range; FULN, fold of the upper limit of the normal range; GGT,
gamma-glutamyl transpeptidase; HCC, hepatocellular carcinoma; HR, hazard ratio; IE, ileal exclusion; IQR, interquartile range; LTX, liver trans-
plantation; OR, odds ratio; PEBD, partial external biliary diversion; PFIC, progressive familial intrahepatic cholestasis; sAT, serum aminotransferase;
sBA, serum bile acid.
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and requires surgical intervention. Orthotopic liver
transplantation (LTX) is widely employed as are techni-
ques to reduce bile salt recirculation, including partial
external biliary diversion (PEBD) and, less frequently,
ileal exclusion (IE).(7,8) PEBD interposes a small bowel
segment between the gallbladder and anterior abdomi-
nal wall, and bile and bile salts are lost through this seg-
ment.(7) IE anastomoses proximal ileum to caecum,
shunting chyme with bile salts past distal ileum into
feces where bile salts are lost.(9) Case reports and case
series suggest that outcomes of these procedures vary,(9-
21) but a comprehensive comparison stratified by genetic
diagnosis has been lacking. Here, we present clinical
and laboratory data from 102 patients with PFIC,
genetically defined as FIC1 or BSEP deficiency, who
underwent one or more of these procedures.
Patients and Methods
PATIENTS
Clinical data were collected from a large cohort of
patients with PFIC through centers with approved
human study protocols and conforming to the ethical
guidelines of the 1975 Declaration of Helsinki, as
described.(3) Participants had surgeries between 1985
and 2004 inclusive.(3) Criteria for inclusion were a clin-
ical diagnosis of low-GGT PFIC and mutation(s) in
ATP8B1 (FIC1 patients) or ABCB11 (BSEP patients).
From this database of 145 patients, we identified
patients who had undergone PEBD, IE, and/or LTX;
57 patients underwent PEBD, 6 patients underwent
IE, and 64 patients underwent LTX. Data from 7
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patients (5 BSEP, 2 FIC1) who underwent LTX were
excluded from this analysis as substantially described
elsewhere.(22) A total of 42 FIC1 and 60 BSEP
patients underwent one or more of these surgeries and
were included. The reported race of these 102 partici-
pants was as follows: 85 white, 10 mixed ancestry (7
Hispanic, 2 Asian/Hispanic, and 1 African American),
3 Native American, 2 Asian, and 2 unknown. Subse-
quent to our prior publication,(3) additional mutation
screening was performed (when DNA was available) in
patients in whom only one mutated allele had previ-
ously been found. Consequently, only 5 BSEP patients
and no FIC1 patients included in this study have a
mutation detected on only one allele.
Data collection was retrospective, and not all
requested information was available for each patient.
The number of patients (n) for whom data were avail-
able is indicated for each variable. We analyzed find-
ings to assess the outcomes after surgery.
PRURITUS
Pruritus data were collected as written descriptions
by clinicians completing the study data collection
form. We resolved these comments into the following
categories: no improvement, partial improvement, or
complete resolution, and subclassified as either tran-
sient or sustained until the most recent data collection.
For statistical analysis, outcomes were dichotomized to
sustained improvement (partial or complete) versus no
sustained improvement (no or transient improvement).
GROWTH
Presurgical height and weight were the last available
values prior to the indicated surgery. Postsurgical
height and weight were the last available values at least
1 year after surgery.
PUBERTY
Patients for whom data were available were subdi-
vided into those who completed puberty before age 18
years (boys) and 16 years (girls) (normal), those who
completed puberty after those ages (delayed; but now
complete), and those who had not completed puberty
at last data collection despite being past the normal age
window (delayed; still not complete). Only girls aged
at least 16 years and boys aged at least 18 years were
included.
CLINICAL CHEMISTRY
For PEBD, blood chemistry values used were the
most recent available value prior to surgery and the first
measurement from at least 2 months after surgery. For
LTX, only post-LTX values were used, again from at
least 2 months after surgery; where a patient had more
than one measurement available at least 2 months after
LTX, the median value was used. To adjust for differ-
ences in reference ranges between sites, most analyte
values were transformed into multiples (fold) of the
upper or lower limit of the normal range (FULN or
FLLN, respectively). Total bilirubin values were not
normalized but were converted to mg/dL. Alkaline
phosphatase values were not normalized as age-specific
normal ranges were only available from some centers;
absolute values in IU/L were used. Alkaline phospha-
tase values reported as lkat/L from one center were
converted to IU/L by multiplying by 59. Platelet levels
were grouped into below normal, normal, or above
normal categories. For analysis of transaminase activi-
ties post-PEBD compared to pre-PEBD, we defined
the variable serum aminotransferase (sAT) as the
FULN for alanine aminotransferase (ALT) or for
aspartate aminotransferase (AST) if ALT values were
unavailable.(3)
ANALYSIS
Median and interquartile range (IQR) were calcu-
lated for continuous variables. Where necessary to nor-
malize distributions, continuous variables were log-
transformed before analysis, and t tests, paired t tests,
analysis of variance, or mixed-effects linear regression
were used, as appropriate. Analyses were performed
using Graphpad Prism and Quickcalc (Graphpad Soft-
ware, La Jolla, CA) and Statistical Analysis System
versions 9.3 and 9.4 (SAS Institute, Cary, NC).
Where transformed data remained non-normally dis-
tributed, appropriate nonparametric methods were
used, including Mann-Whitney and Kruskal-Wallis
tests. Where estimated effects and confidence intervals
(CIs) were needed despite persistent non-normality,
bias-corrected accelerated bootstrapping was used to
obtain valid CIs, with P values defined as 1 minus the
highest confidence level for which the interval excluded
an effect of zero. Categorical variables were assessed
using Fisher’s exact test or logistic regression, as appro-
priate. We report nominal P values without adjustment
for multiple testing; such adjustment is unhelpful here
because biological relationships among the parameters
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mean that coherent sets of results often reinforce rather
than detract from one another.(3)
Our analyses focused on assessment of univariate
associations with gene and for PEBD also with muta-
tion group. For PEBD and LTX, we also assessed
these potential confounding factors: sex, year of birth,
year of surgery, and age at surgery. For LTX, we addi-
tionally assessed living related versus nonrelated donor
and reported medication use after LTX as potential
confounding factors. For post-LTX blood biochemis-
try, linear-mixed models analysis was performed, fac-
toring in gene and time post-LTX (the latter as both
fixed and random effects). Dichotomized outcomes,
such as whether an analyte was normal, were analyzed
by logistic regression models, with random intercept
terms included when using multiple measurements
from the same patients. Additional analyses assessed
the influence of potential confounders. For analyses
yielding small P values for both genetic category and
potential confounding factors, we tested the robustness
of gene and mutation effects with respect to the poten-
tial confounders, using bivariate and multivariate anal-
yses (where computationally feasible).
For survival analysis, poor outcome after PEBD was
defined as progression to histologically proven cirrho-
sis, listing for or receiving LTX, or death. (One patient
had PEBD replaced with IE due to recurrent cholan-
gitis [Fig. 1; patient #3] and was not included in this
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FIG. 1. Timeline of surgeries in patients receiving IE. Of 6 patients who underwent IE, 3 (patient numbers 3, 4, and 6, spread across
gene and mutation categories) remained with IE for 4 years. Of the remaining 3, 2 (patient numbers 3 and 5) proceeded to PEBD
or LTX within 6-7 months and the third (patient number 1) had a short follow-up time. A brief summary of outcomes for each
patient follows, incorporating available information: For patient 1, partial improvement in pruritus was reported but follow-up time
was short. For patient 2, incomplete response to IE was reported and improvement was noted after PEBD was performed. sBAs were
normal for a time after IE in patient 3, but this patient experienced complications (recurrent cholangitis, pancreatitis, pain, weight
loss, requirement for total parenteral nutrition) as well as worsening cholestasis and jaundice and was ultimately referred for LTX. For
patient 4, sBA normalized after IE and remained normal at the last available testing date, >3.5 years after IE; some pruritus was
reported, and the patient was on ursodeoxycholate. Patient 5 was referred for LTX soon after IE. For patient 6 post-IE, minimal pru-
ritus was reported and sBA demonstrated a sustained improvement of >50% (although remaining elevated).
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analysis.) Time was measured from PEBD to the first
poor outcome or last follow-up. We used the Kaplan-
Meier method to plot post-PEBD survival without a
poor outcome by mutation group. Risk estimates,
including hazard ratio (HR) and 95% CI, were deter-
mined using Cox proportional hazards regression.
Results
Two common European mutations, D482G and
E297G, have been identified in BSEP. Laboratory
data suggest that these mutations may result in partial
function of BSEP and thus a less severe phenotype
than those that wholly eliminate BSEP expression or
function.(23-29) Before surgical intervention, disease in
PFIC patients with the D482G mutation tends to pro-
gress less rapidly than in patients with other BSEP
mutations.(3) Therefore, we analyzed patients with
either of these two mutations separately before LTX.
The designation BSEP-D482G refers to patients het-
erozygous or homozygous for this mutation; likewise
for BSEP-E297G. One patient was a compound het-
erozygote for both mutations and was included in the
BSEP-D482G group. These two groups are combined
in some analyses as BSEP-common. BSEP patients
without these mutations are referred to as BSEP-
other. No similar subgroups were identified within the
FIC1 deficiency group.
PEBD
Of the 145 PFIC patients with FIC1 or BSEP dis-
ease included in the original study cohort,(3) 57 under-
went PEBD during the study period (36% of all FIC1
patients and 42% of all BSEP patients) (Table 1). Of
the 51 BSEP-common patients, 49% underwent
TABLE 1. DEMOGRAPHIC AND GENETIC FEATURES OF PATIENTS WHO UNDERWENT PEBD
BSEP
Common
P*
Feature FIC1 All BSEP D482G E297G Other (FIC1 vs. All BSEP)
Patients (n) 22 35 11 14 10
Median year of birth
(range)
1995
(1977-2002)
1994
(1969-2001)
1994
(1980-1997)
1993
(1987-2001)
1997
(1969-2000)
0.41
Median age in years at PEBD (IQR) 1.6 (0.8-6.5) 2.3 (1.4-4.8) 2.9 (2.1-10.7) 2.3 (1.1-3.1) 2.0 (1.4-4.8) 0.38
% With older affected sibling 32% 29% 18% 36% 30% 1.00
% Male 32% 60% 64% 64% 50% 0.057
Median years with PEBD (IQR) 2.4 (1.3-4.6) 4.6 (1.2-6.2) 5.2 (4.8-6.2) 5.0 (1.6-9.2) 1.0 (0.7-1.2) 0.34
These data were available for all participants.
*Fisher’s exact test (2-tailed), Wilcoxon rank sum, or Kruskal-Wallis tests, as appropriate; a number of subgroup comparisons were
significant; see text.
TABLE 2. PRURITUS RESPONSE TO PEBD
Impact on Pruritus
FIC1
(n 5 21)
BSEP
All BSEP
(n 5 34)
Common
Other
(n 5 9)
D482G
(n 5 11)
E297G
(n 5 14)
No improvement 4 (19%) 8 (24%) 1 (9%) 3 (21%) 4 (44%)
Partial improvement Transient 4 (19%) 4 (12%) 0 (0%) 2 (14%) 2 (22%)
Sustained 8 (38%) 11 (32%) 4 (36%) 6 (43%) 1 (11%)
Complete resolution Transient 1 (5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Sustained 4 (19%) 11 (32%) 6 (55%) 3 (21%) 2 (22%)
Two patients are excluded from the table: 1 FIC1 patient had complete resolution of pruritus, but the surgery was performed shortly
before completion of data collection so it is unknown whether the response was transient or sustained. One other BSEP patient had
no information on pruritus response provided.
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PEBD while 30% of the 33 BSEP-other patients did
(Fisher’s exact test; P 5 0.11).
The year of birth, age at PEBD, and proportion of
patients with older affected siblings were comparable
between FIC1 and BSEP deficiencies (Table 1). Of
those having PEBD, a greater proportion of FIC1
patients were female, while a greater proportion of
BSEP patients were male (P 5 0.042 in the subgroup
comparison FIC1 versus BSEP-common; P 5 0.057
overall). Median time with PEBD was defined as time
between PEBD and LTX, IE, or last follow-up,
whichever came first. In one case, IE was undertaken
after PEBD due to recurrent cholangitis. BSEP-
common had the longest median time with PEBD,
while BSEP-other had the shortest (P 5 0.0009);
FIC1 patients were intermediate (P 5 0.020 versus
BSEP-common; P 5 0.039 versus BSEP-other)
(Table 1). Medication data were available for 21
TABLE 3. PEBD OUTCOMES
Feature
FIC1
(n 5 22)
BSEP
P*,
Common BSEP vs.
Other BSEP
P*,
FIC1 vs.
Other BSEP
All BSEP
(n 5 35)
Common
Other
(n 5 10)
D482G
(n 5 11)
E297G
(n 5 14)
Progressed to cirrhosis‡, 0/20 (0%) 5/30 (17%) 0/10 (0%) 2/11 (18%) 3/9 (33%) 0.143 0.023
LTX or listing 6/22 (27%) 11/35 (31%) 1/11 (9%) 3/14 (21%) 7/10 (70%) 0.0039 0.049
Deceased 0/22 (0%) 3/35 (9%) 1/11 (9%) 2/14 (14%) 0/10 (0%) 0.542 †
Poor outcome§ 6/22 (27%) 14/35 (40%) 2/11 (18%) 5/14 (36%) 7/10 (70%) 0.053 0.049
Each cell shows total n (denominators). P values <0.05 are noted in bold. For all features in this table, P values for all BSEP versus
FIC1 and for common BSEP versus FIC1 did not reach significance. *Two-tailed Fisher’s exact tests; †P value not calculable. ‡,Pro-
gression to cirrhosis excludes patients who had cirrhosis at the time of diversion. Six patients (1 D482G carrier, 3 E297G carriers,
and 2 FIC1 patients) had been diagnosed with cirrhosis prior to diversion. §Poor outcome was defined as one or more of the follow-
ing: progression to cirrhosis, listing for or performance of LTX, or death. Three patients, all with one or two copies of E297G, devel-
oped HCC after PEBD; of these patients, 2 died and 1 had LTX. A third patient who was homozygous for D482G died due to
end-stage liver disease approximately 5 years after PEBD.
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FIG. 2. Probability of survival
without a poor outcome after
PEBD, by mutation group.
Patients were followed from
PEBD to the first poor out-
come (progression to cirrhosis,
listing for or receiving a liver
transplant, or dying) or last
follow-up. Number at risk
reflects the number of patients
remaining at risk for a poor
outcome at each time point.
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patients of whom 9 (43%) received choleretic medica-
tion after PEBD (4/7 FIC1, 1/3 BSEP-D482G, 2/7
BSEP-E297G, 2/4 BSEP-other).
EFFECT OF PEBD ON PRURITUS
Overall, no difference in the proportion of FIC1
versus BSEP patients with sustained improvement in
pruritus was detected (P 5 0.58). Most FIC1 patients
(81%) experienced subjective improvement of pruritus
after PEBD, with sustained improvement in 57%
(Table 2). All but 1 BSEP-D482G patient had sus-
tained pruritus improvement as did 64% of BSEP-
E297G patients. When combined, BSEP-common
showed a 76% sustained response; in contrast, this
was reported in only 33% of BSEP-other patients
(Table 2). Collectively, sustained response was more
likely among BSEP-common than BSEP-other
patients (odds ratio [OR], 6.3; 95% CI, 1.2-33.4; P 5
0.030). Testing for potential confounding factors
revealed that older age at PEBD and earlier year of
birth were associated with greater chances of sustained
improvement in pruritus (P 5 0.0062, using ln[age]
and 0.018, respectively). In multivariate analysis incor-
porating age at surgery and year of birth as well as
genetic category, BSEP-common remained more likely
than BSEP-other to have sustained response (OR, 8.1;
95% CI, 1.2-55.9; P 5 0.035).
PATIENT AND LIVER SURVIVAL
AFTER PEBD
No difference in the frequency of clinically impor-
tant poor outcomes of PEBD was detected between
FIC1 and BSEP patients (Table 3). A greater propor-
tion of BSEP-other compared to FIC1 patients pro-
gressed to cirrhosis. BSEP-other patients were also
more likely to be listed for or to undergo LTX than
FIC1 or BSEP-common patients. Survival with
PEBD without any of the three poor outcomes was
evaluated in univariate analysis (Fig. 2), and BSEP-
other patients fared worst. Compared with BSEP-
other patients, risk of poor outcome was reduced for
FIC1 (HR, 0.16; 95% CI, 0.05-0.51; P 5 0.0021),
BSEP-D482G (HR, 0.09; 95% CI, 0.02-0.44; P 5
0.0032), and BSEP-E297G patients (HR, 0.20; 95%
CI, 0.06-0.64; P 5 0.0067). Older age at PEBD was
associated with decreased risk of poor outcome (using
ln[age], P 5 0.03). Both mutation group (P 5 0.003
or lower for all comparisons) and age (P 5 0.005)
remained significant in bivariate analyses.
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GROWTH
Height and weight were assessed where data were
available before and at least 1 year after surgery (Sup-
porting Table S1). A majority of FIC1 and BSEP
patients were lower than the tenth percentile for height
and weight before surgery; both height and weight
improved in most of these patients in both diseases.
Nearly all available BSEP data were from BSEP-
common patients. (No statistical analysis was
attempted.)
BLOOD BIOCHEMISTRY
We assessed the impact of PEBD on circulating
biochemistry, using the last available presurgical value
and the first value available at least 2 months after sur-
gery. Three variables showed statistically and clinically
relevant changes (Table 4). Bilirubin and serum bile
acid (sBA) fell after PEBD in FIC1 and BSEP
patients. Bilirubin and sBA fell in BSEP-D482G and
BSEP-E297G patients but not in the few BSEP-other
patients for whom data were available. Before surgery,
values for sAT were less elevated in FIC1 than in
BSEP patients. There was little change in sAT for
FIC1 patients, but sAT fell in BSEP patients overall
as well as in BSEP-D482G and BSEP-E297G
patients. For these analytes, we also determined the
proportion of patients with clinically meaningful
changes (see Supporting Table S2). Because patients
with good outcomes were more likely to have pre-
PEBD and post-PEBD sBA data available (P 5
0.005), improvement in sBA may be overestimated.
ELECTROLYTE IMBALANCE AND
OTHER COMPLICATIONS
An open-ended question about complications of
PEBD yielded reports of electrolyte imbalance and/or
dehydration related to high bile output in 3 BSEP
patients (1 accompanied by bleeding from stoma) and
3 FIC1 patients. In 1 FIC1 patient, this led to cardiac
arrest. Also reported were cholangitis (1 BSEP and 2
FIC patients), no or low bile flow or bile stagnation (2
FIC1 patients), stone/obstruction/occlusion (1 BSEP
and 2 FIC1 patients), and high bile output with bleed-
ing from the stoma but without reported electrolyte
imbalance or dehydration (1 BSEP patient).
IE
Six patients underwent IE. Reported responses var-
ied with too few patients to compare between catego-
ries. For a summary of outcomes, see Fig. 1.
LTX
Of the 145 patients with severe FIC1 or BSEP defi-
ciency in the study cohort,(3) 64 underwent LTX dur-
ing the study period; our analysis here includes 57 of
these patients. The median follow-up time after LTX
was similar between diseases, but BSEP patients had
LTX at a younger age than FIC1 patients; consistent
with this, the BSEP patients were born more recently
(Table 5). Of the 33 BSEP patients with transplants,
18 were BSEP-common and 15 BSEP-other. BSEP
patients were analyzed as a single group as the protein
is thought to have significant function only in the liver
TABLE 5. LTX: DEMOGRAPHICS AND OUTCOMES
Feature FIC1 BSEP P
# Undergoing LTX 24 33
Median years with LTX (IQR) 3.6 (1.1-7.1) n 5 24 3.6 (1.1-6.1) n 5 33 0.99
Median age (years) at LTX (IQR) 5.8 (3.0-12.1) n 5 24 3.1 (1.9-5.8) n 5 33 0.010
Median year of birth (full range) 1991 (1976-1999) n 5 24 1996 (1978-2003) n 5 33 0.030
Proportion male 8/24 (33%) 16/33 (48%) 0.29
# With older affected sibling 4/24 (17%) 5/33 (15%) 1.00
# Died post-LTX 3/24 (13%) 0/33 (0%) 0.07
# Requiring retransplant 1/24 (4%) 4/33 (12%) 0.39
# With rejection 15/21 (71%) 22/31 (71%) 1.0
# With hepatic steatosis 19/21 (90%) 2/31 (6%) <0.0001
# With diarrhea 17/21 (81%) 2/29 (7%) <0.0001
# Requiring parenteral nutrition 3/20 (15%) 0/29 (0%) 0.062
# With pancreatitis or pancreatic insufficiency 8/20 (40%)
7 pancreatitis
1 insufficiency
0/29 (0%) 0.0003
P values <0.05 are noted in bold.
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and therefore genotype is not expected to influence
LTX outcome. The exception would be the possibility
of alloantibody formation (see Discussion).
Overall, outcomes after transplantation were good
with few deaths (5%, all FIC1 patients) or patients
requiring retransplantation (9%) (Table 5). Two of the
three deaths were due to nonspecific complications of
LTX (1 had respiratory failure, another had multiple
surgical complications). The third child died, aged 12,
of complications following subsequent small bowel
transplantation.
The overall reported incidence of rejection (chronic,
acute, or unspecified) was not significantly different
between the two groups (Table 5). Retransplantation
was undertaken in 4 BSEP patients due to surgical
complications in 1, chronic rejection in a second, and
multiple problems in the remaining 2, including auto-
immune hepatitis in 1 and giant cell hepatitis in the
other. One FIC1 patient underwent retransplantation
twice for technical complications within 1 week of the
initial LTX.
Five BSEP and 4 FIC1 patients underwent living-
related-donor transplantation (7 from obligate hetero-
zygote parents, 1 from an uncle, and 1 from an
unspecified relative). Such transplantation was not
associated with detectably different outcomes from
unrelated-donor LTX: 1 such FIC1 patient and no
BSEP patients required retransplantation. All living-
related-donor transplant recipients were alive at last
follow-up.
Management after LTX varied according to the
local protocol (Supporting Table S3).
LIVER FUNCTION AFTER LTX
Allograft steatosis was reported in only 2 of 31
BSEP patients for whom biopsy reports after LTX
were available but was found in 19 of 21 such FIC1
patients (Table 5). An additional FIC1 patient was
diagnosed with steatosis based upon ultrasonographic
findings unconfirmed by biopsy.
Consistent with the finding of steatosis in FIC1
patients, serum levels of ALT and AST (2 months
after LTX) were mildly elevated for most FIC1
patients but were in the normal range for most BSEP
patients (Table 6). A small number of FIC1 patients
had elevated platelet counts (4/18) suggestive of
inflammation, whereas no BSEP patients did (0/27)
TABLE 6. POST-LTX BLOOD BIOCHEMISTRY: MEDIAN VALUES PER PATIENT FOR EACH DISEASE
Serum Assay
FIC1
Median
(IQR)
n
BSEP
Median
(IQR)
n
P for
FIC1 vs. BSEP*
Effect/Trend
(95% CI)
ALT (FULN) 1.6 (1.1-2.3)
n 5 16
0.8 (0.5-0.9)
n 5 23
<0.0001 97% higher in FIC1
(30%-190% higher)
AST (FULN) 1.6 (1.1-2.2)
n 5 18
0.9 (0.7-1.0)
n 5 27
0.0083 61% higher in FIC1
(17%-107% higher)
Total bilirubin (mg/dL) 0.4 (0.3-0.6)
n 5 18
0.9 (0.5-1.0)
n 5 26
0.46 0.2 mg lower in FIC1
(0.5 mg lower to 0.3 mg higher)
GGT† (FULN) 0.7 (0.3-1.6)
n 5 16
0.3 (0.2-0.8)
n 5 27
0.037 77% higher in FIC1
(4%-274% higher)
Albumin‡ (FLLN) 1.0 (0.8-1.0)
n 5 18
1.1 (1.0-1.2)
n 5 18
0.0052 17% lower in FIC1
(7%-24% lower)
Total protein (FLLN) 1.0 (1.0-1.2)
n 5 17
1.2 (1.1-1.2)
n 5 17
0.06 9% lower in FIC1
(16% lower to 0.5% higher)
Cholesterol (FULN) 0.4 (0.3-0.6)
n 5 8
0.6 (0.5-0.7)
n 5 19
0.027 37% lower in FIC1
(8%-57% lower)
Hemoglobin (FLLN) 1.0 (0.9-1.1)
n 5 16
1.1 (1.1-1.2)
n 5 24
0.0007 16% lower in FIC1
(5%-27% lower)
ALP (IU/L) 292 (199-445)
n 5 19
255 (212-319)
n 5 20
0.43 14% higher in FIC1
(20% lower to 70% higher)
Hematocrit (FLLN) 1.0 (1.0-1.1)
n 5 11
1.1 (1.0-1.3)
n 5 21
0.24 8% lower in FIC1
(20% lower to 6% higher)
Triglycerides (FULN) 0.3 (0.3-0.5)
n 5 8
0.3 (0.2-1.0)
n 5 12
0.95 7% lower in FIC1
(58% lower to 118% higher)
P values <0.05 are noted in bold.
n, number of patients for whom data were available. Median value per patient was used for patients for whom results of multiple tests
were available. *Comparison of geometric means, factoring in time. †The apparent gene effect on GGT may be due to effects of year
of LTX and age at LTX. ‡Additional analysis indicates some of the apparent gene effect may be accounted for by an effect of steroid
use. Abbreviation: ALP, alkaline phosphatase.
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(likelihood ratio P 5 0.015; Supporting Table S4).
Bilirubin levels normalized in nearly all patients and
were similar between diseases.
Circulating GGT levels were also higher in FIC1
than in BSEP patients after LTX (Table 6; Supporting
Table S4); however, in testing for confounding varia-
bles, higher GGT levels were also associated with older
age at transplant and earlier year of transplant. In mul-
tivariate analyses, the gene effect on GGT no longer
attained P < 0.05, while age and year did.
INTESTINAL DISEASE AND
EVIDENCE OF MALABSORPTION
Diarrhea is a known complication of LTX; it is also
a frequent feature of FIC1 deficiency before LTX.(3)
Diarrhea after LTX was reported in only 7% of the
BSEP-deficient group but was reported in 81% of the
FIC1-deficient group (Table 5). Of the 17 FIC1
patients with diarrhea after LTX, only 8 had the prob-
lem before LTX. In 3 FIC1 patients, diarrhea after
LTX had sufficient nutritional impact that parenteral
nutrition was necessary (Table 5); 1 of these patients
underwent a subsequent small bowel transplant.
Consistent with the much greater incidence of diar-
rhea after LTX in FIC1 patients, circulating albumin
and total protein levels after LTX in these patients
were more likely to be below normal range than in
BSEP patients (Supporting Table S4). Also consistent
with poorer nutritional status, circulating cholesterol
levels and hemoglobin levels were lower in FIC1
patients than in BSEP patients (Table 6).
PANCREATIC DISEASE
Pancreatic problems can occur in FIC1 deficiency.(3)
Seven FIC1 patients had pancreatitis after LTX and 1
had exocrine insufficiency (Table 5). Three of these
8 patients had known pancreatic disease before LTX.
No BSEP patients had evidence of pancreatic disease
after LTX.
GROWTH
Growth failure is a major problem in all forms of
cholestatic liver disease in children. We previously
demonstrated that it is notably worse in FIC1 defi-
ciency than in BSEP deficiency before surgical inter-
vention.(3) Growth status was assessed using data
collected >1 year after LTX to allow for catch-up
growth. Differences in both height and weight
between the two conditions were marked. Only 35%
and 31% of FIC1 patients were above the third percen-
tile for height and weight, respectively, in contrast to
                                                                                                                                      
FIG. 3. Comparison of growth before and after LTX. As with Supporting Table S5, patients’ growth was binned into three catego-
ries: 10th percentile, 3rd-10th percentile, and <3rd percentile. The categories in the graphs are as follows: patient already 10th per-
centile prior to surgery and remained in that category post-LTX; patient growth improved by one to two categories post-LTX; patient
growth remained in the same category after LTX; patient growth category worsened post-LTX.
                                                                                                                                      
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88% and 90% of BSEP patients (height, P 5 0.0004
and weight P < 0.0001, FIC1 versus BSEP, each
binned into 3 percentile bands; Supporting Table S5).
Among patients for whom growth data were available
both before and after LTX, FIC1 patients were more
likely to have weight below the tenth percentile before
transplantation compared to BSEP patients (P 5
0.0456, Fisher’s exact test; Fig. 3). After LTX, there
was a trend toward FIC1 patients being less likely than
BSEP patients to experience catch-up weight gain
(P 5 0.10, Fisher’s exact test; Fig. 3).
PUBERTY IN PATIENTS WHO HAD
UNDERGONE PEBD AND/OR LTX
At the time of the last data collection, 13 patients
(10 girls and 3 boys) had undergone PEBD and/or
LTX and were at or past the normal age for puberty
completion (16 years, girls; 18 years, boys). Among
FIC1 patients, 1/6 completed puberty within the nor-
mal age range, 2/6 completed puberty after the normal
age window, and 3/6 had not completed puberty.
Among BSEP patients, 5/7 completed puberty within
the normal age range, 1/7 completed puberty after the
normal age window, and 1/7 had not completed
puberty (Supporting Table S6). There was a trend (P
5 0.10, Fisher’s exact test) toward FIC1 patients being
more likely to have delayed or incomplete puberty.
When only patients who had undergone LTX were
evaluated, 2/5 FIC1 patients had delayed but com-
pleted puberty and 3/5 had not completed puberty,
while all 4 BSEP patients completed puberty within
the normal window (P 5 0.008, Fisher’s exact test).
Discussion
PEBD
The aim of PEBD is to interrupt bile salt recircula-
tion, to relieve pruritus, and potentially to improve liver
function and overall clinical outcome. Similar propor-
tions of FIC1 and BSEP patients from our original
cohort underwent PEBD. Our retrospective data indi-
cate that some patients in all genotype groups responded
with improvements in pruritus and biochemistries.
A majority of patients with FIC1 or BSEP deficien-
cies had sustained subjective improvement in pruritus.
However, patients with one of the BSEP-common
mutations (D482G or E297G) were more likely to
have a sustained response than were BSEP patients
with other mutations.
Blood levels of bilirubin, bile acids, and transaminases
improved or remained good after PEBD in most FIC1
and BSEP patients; however, in FIC1 disease, transami-
nase activities were only modestly elevated before PEBD
and did not detectably change after surgery. Insufficient
biochemical data from before and after PEBD were
available from BSEP-other to allow comparison of
results between BSEP-common and BSEP-other.
Clinical outcome of PEBD was assessed by avoid-
ance of poor outcomes, including death, development
of cirrhosis, LTX, or listing for LTX. On this basis,
BSEP-other patients fared worse than patients in other
groups. The data presented here were collected prior to
increased understanding of differing outcomes in
BSEP versus FIC1 deficiency and before realization
that mutation type within BSEP deficiency makes a
difference to the risk of hepatocellular carcinoma
(HCC).(6) Patient management decisions were there-
fore likely based on clinical rather than genetic find-
ings. Three patients developed HCC after PEBD and
before the last data collection; 1 received a successful
transplant, and the other 2 died. Interestingly, all 3
had at least one copy of E297G, which would have
been predicted to confer a lower risk of HCC than
some BSEP genotypes.
In this cohort, patients who underwent PEBD at an
older age were more likely to have sustained improve-
ment in pruritus and decreased risk of poor clinical out-
come compared to patients who underwent PEBD at a
younger age. Analyses taking both age and gene/muta-
tion into account suggest that this effect may not be
completely explained by patients with inherently milder
disease having PEBD at a later age than those with
more severe disease. Assessment of pruritus is, however,
affected by patient age and communication skills.
PEBD results in clinical improvement in many
patients with FIC1 or BSEP deficiency. However, our
data support the clinical impression that PFIC due to
BSEP deficiency can be divided into different clinical
subgroups. It was previously suggested that patients
bearing the E297G BSEP mutation may have a better
response to PEBD than other BSEP patients.(22) Results
in our larger cohort indicate that PEBD may be espe-
cially helpful to those bearing mutation(s) likely to retain
residual protein function, including either BSEP-
common mutation.
LTX
Liver transplantation is a major therapeutic tool in
the management of PFIC. Unlike BSEP, FIC1 is
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widely expressed. It is not surprising, therefore, that
responses to LTX differed between BSEP and FIC1
patients. Graft and patient survival were good in
both groups. Patient survival trended worse in FIC1
deficiency; survival of the initial graft was, however,
similar. The figures compare favorably with those in
other pediatric LTX series from the late 1980s
onward.(30,31)
In this study, BSEP patients came to LTX younger
than FIC1 patients. As the data for this study were
assembled before the realization that BSEP patients
may be at significant risk of native-liver HCC, aware-
ness of HCC risk is unlikely to explain this trend.(6,32)
In this cohort, 2 patients received transplants after a
diagnosis of HCC, 1 of whom had previously under-
gone PEBD (discussed above); both were well at last
follow-up. The patient without PEBD was from the
BSEP-other group.
LTX resolved cholestasis in both cohorts; however,
as hypothesized based on tissue sites of protein expres-
sion, extrahepatic complications were worse with FIC1
deficiency than with BSEP deficiency. BSEP patients
were free of pancreatic disease, while a higher propor-
tion of FIC1 patients manifested pancreatic disease
after LTX than before (40% versus 12%).(3) This
increase in pancreatic disease may be directly related to
LTX or may simply reflect progression of extrahepatic
disease in FIC1 patients over time.
FIC1 is highly expressed in the small and large
intestine of healthy individuals. Diarrhea after the
transplant was 12-fold more common with FIC1 than
BSEP deficiency. After LTX, FIC1 patients also often
have biochemical markers of malnutrition and may
have poorer catch-up growth and more persistent
pubertal delay.
Steatosis in the allograft liver has been reported in
FIC1 patients but is now confirmed in this large
genetically characterized cohort and contrasted with
the status of livers transplanted into BSEP-deficient
patients. In this cohort, most FIC1-deficient patients
had graft steatosis and accompanying elevated trans-
aminase activities with otherwise acceptable graft
function.
The concept of alloantibody formation after LTX
had not been proposed when collection of these data
was completed. It is not clear if this complication con-
tributed to the outcomes among the BSEP patients.
Four BSEP patients underwent retransplantation, of
whom only 1 was described as having giant cell hepati-
tis. None of the patients who received the retransplant
had two protein truncating mutations, which would
have put them at the highest risk of alloantibody
formation.(33,34)
Not only is the gastrointestinal tract abnormal in
FIC1 deficiency but an abnormality in gut–liver signal-
ing exists.(35,36) The situation appears to change when
a genetically normal transplanted liver is coupled with
a FIC1-deficient intestine. The steatosis seen after
LTX in FIC1 deficiency could be a manifestation of
altered signaling in this unusual circumstance. Gastro-
intestinal dysfunction and pancreatic injury may con-
tribute to diarrhea, poor growth, and low albumin and
hemoglobin after LTX in FIC1 deficiency. There are
several reports in the literature of different biliary
diversion procedures at or after LTX in FIC1-deficient
patients(37-39); PEBD seems to have been effective in
mitigating the steatosis and diarrhea in most of these
cases. Our data reinforce the opinion that FIC1 defi-
ciency is a multisystem disease and that isolated LTX
should not be considered a cure.
Several previous case series have presented data on
the outcomes of surgical management of PFIC. Unfor-
tunately, those studies have had small numbers or
lacked systematic genetic diagnoses.(7-21) Our data
comprise the largest set of outcomes of PEBD or LTX
in genetically diagnosed PFIC. Results from this
cohort can be used to help guide clinical management.
In particular, the likely outcomes after different inter-
ventions can to some extent be anticipated. Patients
with BSEP deficiency harboring either the E297G or
D482G mutation can be expected to do well after
PEBD, although 3 patients developed HCC in the
E297G group. This contrasts with our previous find-
ing that patients with missense mutations have a lower
risk of HCC than those with two protein-truncating
mutations.(6) PEBD can also be expected to result in a
good outcome in most FIC1 patients. As FIC1 defi-
ciency is a multisystem disease, extrahepatic manifesta-
tions and graft dysfunction complicate and limit the
utility of LTX. BSEP deficiency, on the other hand, is
a primarily hepatic disorder and generally responds
well to LTX.
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